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Abstract
Inhibitor of DNA-binding-1 (ID1) transcription factor is essential for the proliferation and
progression of many cancer types including leukemia. However, the ID1 protein has not yet been
therapeutically targeted in leukemia. ID1 is normally polyubiquitinated and degraded by the
proteasome. Recently, it has been shown that USP1, a ubiquitin specific protease, deubiquitinates
ID1 and rescues it from proteasome degradation. Inhibition of USP1 therefore offers a new avenue
to target ID1 in cancer. Here, using a Ubiquitin-Rhodamine-based high throughput screening, we
identified small molecule inhibitors of USP1 and investigated their therapeutic potential for
leukemia. These inhibitors blocked the deubiquitinating enzyme activity of USP1 in vitro in a
dose-dependent manner with an IC50 in the high nanomolar range. USP1 inhibitors promoted the
degradation of ID1 and, concurrently, inhibited the growth of leukemic cell lines in a dose
dependent manner. A known USP1 inhibitor, Pimozide, also promoted ID1 degradation and
inhibited growth of leukemic cells. In addition, the growth of primary Acute Myeloid Leukemia
(AML) patient-derived leukemic cells was inhibited by a USP1 inhibitor. Collectively, these
results indicate that the novel small molecule inhibitors of USP1 promote ID1 degradation and are
cytotoxic to leukemic cells. The identification of USP1 inhibitors therefore opens up a new
approach for leukemia therapy.
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INTRODUCTION
ID1 (inhibitor of DNA binding 1) protein is a member of the helix-loop-helix (HLH) family
of transcriptional regulatory proteins which consists of four members, ID1-ID4 (1, 2). Basic
HLH (bHLH)-family of transcription factors are key regulators of cellular development and
differentiation. The bHLH proteins (e.g. E2A, E2-2, HEB) form homodimers or
heterodimers with other tissue-specific bHLH proteins (e.g. MyoD, SCL/tal1), bind DNA
upon dimerization, and activate transcription of differentiation-associated proteins. The ID-
family of HLH proteins can also form dimers with bHLH proteins (3). However, the ID-
bHLH heterodimers are transcriptionally inactive and are unable to bind to the DNA since
ID proteins lack a basic DNA binding domain (2). Accordingly, ID proteins antagonize the
functions of bHLH proteins and inhibit the bHLH protein-mediated transactivation of genes
which promote cellular differentiation. ID proteins, therefore, are also termed inhibitors of
differentiation. In addition to binding to the bHLH proteins, ID proteins can also interact
with non-bHLH proteins and antagonize their function (4).
ID1, one of the ID proteins, is known to play a role in cellular transformation. It is
overexpressed in a variety of human cancer types, including pancreatic, cervical, ovarian,
prostate, breast, colon and brain cancer (5-11). In most of these cancer types, high ID1
expression correlates with poor prognosis and increased chemoresistance (7, 9, 10, 12, 13).
Moreover, functional studies have demonstrated that ID1 can promote cell proliferation,
inhibit differentiation, delay cellular senescence in primary human cells, and promote cell
migration and the metastatic phenotype of cancers (14). ID1 function is also required for
maintaining the ‘stemness” of many normal and malignant tissues (10, 11, 15).
Recent studies indicate that ID1 is also an activator of leukemic cell growth. First, Tang et al
(16) observed high levels of ID1 expression in primary AML samples, and high expression
correlated with poor prognosis. Second, ID1 was identified as a common downstream target
of constitutively activated oncogenic tyrosine kinases, such as BCR-ABL and TEL-
ABL(17). Third, ID1 can immortalize hematopoietic progenitors in vitro and promote a
myeloproliferative disease in mice in vivo (18). Moreover, knockdown of ID1 expression
inhibited leukemic cell growth (18). Collectively, these observations suggest that ID1 is a
prime therapeutic target for leukemia and other cancer types. However, suitable drugs to
therapeutically target ID1 have not been developed to date (14). Protein-protein interactions
in the nucleus, such as the interaction of ID1 with HLH factors, are notoriously difficult to
inhibit with small molecules (19).
A recent report offers an alternative strategy for knocking down the ID1 protein-namely,
through inhibition of the ubiquitin specific protease, USP1 (20). USP1 is a deubiquitinating
(DUB) enzyme, which removes polyubiquitin chains from the ID1 protein (20). ID1 is
normally polyubiquitinated and rapidly degraded by the proteasome (21-23). USP1 removes
the polyubiquitin chains and rescues ID1 from degradation. Selectively knocking down
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USP1 using shRNA results in a rapid degradation of ID1 in osteosarcoma cells. Importantly,
USP1 knockdown results in decreased mesenchymal cell proliferation, and enhanced
differentiation of osteosarcoma cells which overexpress USP1 and ID1 (20), providing a
rationale for differentiation therapy of many cancer types including leukemia (e.g. acute
myelogenous leukemia (AML), chronic myelogenous leukemia (CML)). We therefore
reasoned that pharmacologic inhibition of USP1 would promote ubiquitin-mediated
degradation of ID1 protein, resulting in differentiation and growth inhibition of immature
leukemic cells. Our laboratory has previously shown that human USP1 forms a stable
complex with its binding partner, USP1 associated factor 1 (UAF1) (24). USP1 by itself
exhibits low DUB activity; however, this activity is significantly enhanced when bound as a
USP1/UAF1 complex. Using high throughput screening, we identified a small molecule
inhibitor of the USP1/UAF1 complex. We describe here a novel small molecule (C527), and
multiple derivatives, that inhibit USP1 catalytic activity, promote ID1 degradation, and
inhibit leukemic cell growth.
MATERIAL AND METHODS
High Throughput Screening
The USP1/UAF1 complex was prepared as described previously (24) (Figure 1) and the
protein complex was used for high throughput screening. The fluorogenic ubiquitin-
Rhodamine (Ub-Rhodamine) based enzyme assay was established in a 384-well format for
high throughput screening. The reaction buffer containing free ubiquitin and USP1/UAF1
enzyme complex was added in 384 well plates using automated liquid handling robot-Bio-
Tek Microfill (Bio-Tek Instrments Inc., VT), followed by addition of the compounds (in
DMSO) from the compound library plates to wells using a pin transfer robotic system at a
final concentration of 10 μM. The reactions were then incubated for 30 min at room
temperature followed by the addition of Ub-Rhodamine to initiate the reactions. The enzyme
activity of the USP1/UAF1 complex was determined by measuring the fluorescence of Ub-
Rhodamine. 150,000 compounds were screened from the library plates at the Partners
Center for Drug Discovery, Cambridge, MA. Details of the screen are provided in the
‘supplementary methods” section.
In Vitro Deubiquitination Assays
Purified USP5 enzyme was purchased from Boston Biochem. UCH-L1 and UCH-L3 were
as reported previously (25). USP12/46 was prepared in our laboratory as described (26, 27).
The in vitro enzymatic assays were performed as described previously (24) using ubiquitin-
AMC (Ub-7-amido-4methylcoumarin; Boston Biochem) as a substrate in a reaction buffer
containing 20 mM HEPES-KOH (pH 7.8), 20 mM NaCl, 0.1 mg/ml ovalbumin, 0.5 mM
EDTA and 10 mM dithiothreitol. The fluorescence was measured by FluoStar Galaxy
Fluorometer (BMG Labtech). For the Ub-vinylsulfone (VS) assay, the proteins were
incubated with Ub-VS (Boston Biochem) at 0.5 μM final concentration for 45 min at 30 °C,
followed by the immunoblotting analysis.
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Cells and drug treatments
Leukemic cell lines were grown in RPMI 1640 medium (Invitogen) supplemented with 10%
fetal bovine serum (Invitrogen) and penicillin/streptomycin (Invitrogen). Hela cells and
U2OS cells were grown in DMEM (Invitogen) supplemented with 10% fetal bovine serum
(Invitrogen) and penicillin/streptomycin (Invitrogen). K562 cells were provided by Dr.
Dipanjan Chowdhury (Dana-Farber Cancer Institute, Boston, MA). MOLM14 cells were
provided by Dr. A. Thomas Look (Dana-Farber Cancer Institute, Boston, MA). Luciferase
expressing AML cell lines were provided by Dr. Andrew Kung (Dana-Farber Cancer
Institute, Boston, MA). Mouse osteosarcoma cells were provided by Dr. Stuart Orkin (Dana-
Farber Cancer Institute, Boston, MA). The cells were provided within the last 24 months.
No authentication of the cell lines was done by the authors. USP1 inhibitor C527 and its
derivatives were synthesized and the purity was validated by high-performance liquid
chromatography. Pimozide was purchased from Sigma. Primary human AML patient
samples were collected from DFCI leukemia program under the approval of appropriate
protocols. Cells were treated with DMSO or USP1 inhibitors in appropriate medium for
24-72 hrs. The viable cell counts were determined using Trypan blue staining, Cell TiterGlo
reagent (Promega) or MTT assay. The apoptotic cells were detected using AnnexinV and
7AAD (BD Biosciences) staining according to the manufacturer's instructions using flow
cytometry. For Benzidine staining, the cells were washed twice with PBS and resuspended
in 45 μl of PBS + 5 μl of Benzidine stain solution (0.2% in 0.5 M glacial acetic acid, 3%
H2O2). After 45 min incubation at room temperature, the Benzidine positive cells were
detected by light microscopy.
Antibodies and shRNAs
Western blotting was performed with the following antibodies: anti- USP1 (A301-699A,
Bethyl lab), anti- ID1 (B-8, Santa Cruz), anti-Vinculin (H-10, Santa Cruz), anti-alpha
tubulin (DM1A, Santa Cruz), anti-ID2 (C-20, Santa Cruz), anti-ID3 (C-20, Santa Cruz),
anti-FANCD2 (H-300, Santacruz) and anti-FANCI (28). Doxycyclin-inducible shRNAs in
TRIPZ Lentivirus vectors against human USP1 were purchased from Open Biosystems
(Thermo Scientific). Mature antisense sequence for the shRNAs were
(A)V2THS_171887:TTTATCTTCTCCTACAATC, (B) V2THS_218649:
TTAAGATAGCAAGTATTGC and (C) V2THS_171886:TAAACTTTCACATTCCAAG.
Mouse xenograft experiments
6-8 weeks old athymic nude mice were used for xenograft studies. The mouse experiments
were reviewed and approved by DFCI's Animal Care and Use Committee. 5 × 106 K562
cells were mixed with matrigel (BD Bioscience) (1:1 ratio) and injected subcutaneously into
the flanks of nude mice. When the tumors reached 2 mm3 size, 15 mg/kg Pimozide
(dissolved in 2% DMSO+0.3% Tartaric acid) or Vehicle was administered daily. The tumor
growth was monitored by measuring the size.
Homologous recombination (HR) analysis and immunofluorescence
HR activity was analyzed by DR-GFP reporter as previously described (29). U2OS-DRGFP
cells carrying a chromosomally integrated single copy of HR repair substrate were used.
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Double strand break (DSB)-induced HR in these cells results in restoration and expression
of GFP. Briefly, 24 h after induction of chromosomal DSBs through the expression of I-
SceI, U2OS-DRGFP cells were treated with USP1 inhibitor C527 for 24 h. Cells were then
subjected to FACS analysis to quantify the percentage of viable GFP-positive cells. The
Rad51 foci in cells were detected by immunofluoroscence as described (30) using anti-
RAD51 (Santa Cruz Biotechnology) and Alexa Fluor 488-conjugated secondary antibodies.
The quantification of cells with RAD51 foci was performed by counting the number of cells
with RAD51 foci.
RESULTS
Identification of a novel USP1 inhibitor using high throughput screening
We have previously reported that USP1 by itself exhibits poor DUB activity. However,
when bound to its interacting partner, UAF1, the catalytic activity of USP1 is significantly
enhanced (24). We therefore utilized a purified USP1/UAF1 complex and performed a high
throughput screen to identify a USP1 inhibitors (Figure 1). We used the cDNA encoding a
full length USP1 polypeptide, which had a substitution of GG to AA at amino acid residues
670 to 671 (Figure 1A). We have previously shown that this amino acid change disrupts an
autocleavage site in USP1 but does not alter the interaction of USP1 with UAF1 or the DUB
activity of the complex (24, 31). Human USP1 (with GG to AA mutation) and UAF1
proteins were coexpressed in SF9 insect cells to generate a protein complex with elevated
DUB activity. The USP1/UAF1 protein complex was purified and the purity was confirmed
by coomassie staining (Figure 1B). The stable USP1/UAF1 enzyme complex was then
subjected to a high throughput inhibitor screen, described schematically in Figure 1C. A
small molecule, C527 (heterocyclic tricyclic 1,4-dihydro-1,4-dioxo-1H-naphthalene) (Figure
1D) was identified which inhibited the USP1/UAF1 complex.
USP1 inhibitor C527 has a high affinity for USP1
We next confirmed the ability of C527 to inhibit the USP1/UAF1 complex in a dose-
dependent and time-dependent manner, using Ub-AMC as a substrate (Figure 1E-G).
Pretreatment of USP1/UAF1 with C527 resulted in inhibition of its enzyme activity with an
IC50 of 0.88 ± 0.03 μM. To determine the specificity of C527 in USP1/UAF1 inhibition, we
next examined its ability to inhibit other DUB enzymes in vitro. UAF1 stimulates not only
USP1, but also two other DUB enzymes, USP12 and USP46 (26). We therefore tested C527
for its ability to inhibit the purified USP12/USP46 complex or other DUBs. C527 inhibited
the DUB activity of the USP12/USP46 complex and other DUB enzymes in vitro. However,
the IC50 of C527 for these DUB enzymes was higher in comparison to USP1/UAF1
complex (Table 1). C527 had considerably less inhibitory effect on UCH-L1 and UCH-L3, a
different subclass of deubiquitinating enzymes, referred to as the ubiquitin C- terminal
hydrolases (25), even though they are also cysteine proteases. Taken together, C527 is a
pan-deubiquitinating enzyme inhibitor in vitro, with a high nanomolar IC50 for the USP1/
UAF1 complex.
In order to generate a USP1 inhibitor with improved cellular potency, we chemically
synthesized several analogs/derivatives of C527 and determined their IC50 for USP1/UAF1
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inhibition (data not shown). We then selected a derivative, SJB2-043 (IC50=0.544 μM), for
further studies due to the feasibility of its large-scale chemical synthesis.
USP1 inhibitor SJB2-043 inhibits the enzyme activity of native USP1
We next determined whether SJB2-043 inhibits the DUB activity of native USP1 complexes
isolated from human cells (Figure 1 H, I). For this purpose, we performed competition
assays between SJB2-043 and the ubiquitin (Ub) active site probe HA-Ub-Vinyl sulfone
(HA-Ub-VS) reagent (Figure 1H). This affinity reagent covalently modifies and traps active
DUB enzymes in cell extracts (32). Cells were treated with SJB2-043 for 24 hrs and cell
extracts were incubated with HA-Ub-VS, followed by immunoblotting with anti-USP1 or
anti-HA antibodies. Consistent with our previous studies and the most recent studies by
Piatkov et al (24, 31, 33), USP1 in the untreated cells was detected on western blot as a
doublet; full length USP1 and an auto-cleaved USP1 with only N-terminus (Figure 1I, lane
1). The Ub-USP1 conjugates were generated in the untreated cell lysates and were detected
by an increase in molecular weight of USP1 (Figure 1I, lane 2). However, the formation of
the Ub-USP1 conjugate was inhibited by the addition of SJB2-043 (lanes 4). Ub-aldehyde, a
potent known nonspecific DUB inhibitor, caused a complete loss of USP1-Ub-VS
conjugates in this competition assay (lane 3). SJB2-043 inhibited the Ub-VS labeling of a
limited number of endogenous DUB enzymes (Figure 1I, anti-HA blot). In addition,
SJB2-043 inhibited the labeling of USP1 with Ub-VS in a dose dependent manner
(supplementary figure 1A). Taken together, these data demonstrate that SJB2-043 is an
inhibitor of the native USP1/UAF1 complex.
Novel USP1 inhibitors promote degradation of ID1 in leukemic cells
shRNA knockdown of USP1 results in enhanced proteasome-mediated degradation of ID1
in osteosarcoma cells (20). ID1 degradation in osteosarcoma cells results in mesenchymal
differentiation and decreased cell proliferation. We therefore tested whether small molecule
USP1 inhibitors enhance ID1 degradation in cells. Indeed, USP1 inhibitor C527 promoted
the dose-dependent degradation of ID1 in human U20S osteosarcoma cells (data not shown).
We next tested USP1 inhibitors for their ability to inhibit USP1 in various cell lines. The
K562 cell line (the erythroleukemia cell line derived from a chronic myelogenous leukemia
(CML) patient), was treated with SJB2-043 (Figure 2A) for 24 hrs, and USP1 and ID1
protein levels were determined by Western blotting. Interestingly, the SJB2-043 caused a
dose-dependent decrease in USP1 levels and a concomitant degradation of ID1 protein in the
K562 cells at a micromolar drug concentration (Figure 2B). The decrease in USP1 and ID1
levels by SJB2-043 exposure resulted from proteasomal degradation, since the proteasome
inhibitor, MG-132, restored the levels of both proteins (Figure 2C, supplementary figure
1B).
SJB2-043 also caused a decrease in the levels of other ID proteins, namely ID2 and ID3 in
K562 cells (supplementary figure 1C). To determine whether the decrease in ID1 levels was
secondary to a decrease in USP1 levels, we next generated a K562 stably transfected with a
cDNA encoding doxycycline-induced shRNA to USP1. As expected, doxycycline exposure
of these cells resulted in a dose-dependent decrease in USP1 expression (supplementary
figure 2A). Moreover, depletion of USP1 by siRNA promoted ID1 degradation in K562
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cells (supplementary figure 2B). Importantly, siRNA-mediated knockdown of USP1 in
leukemic K562 cells resulted in growth inhibition, increased apoptosis and cell cycle arrest
(Supplementary figures 2C, 2D, 2E, 2F). Collectively, these results indicated that while
SJB2-043 may have off target effects, it exhibits its activity in K562 cells at least in part by
promoting degradation of USP1 which results in ID1-ID3 degradation.
USP1 inhibitors are cytotoxic to leukemic cells
We next determined whether the USP1 inhibitors are cytotoxic to leukemic cells and
whether the cytotoxicity results from ID1 degradation. K562 leukemic cells were treated
with SJB2-043, and survival and differentiation were assessed. SJB2-043 caused a dose-
dependent decrease in the number of viable K562 cells, with an EC50 of approximately 1.07
μΜ ± 0.08 (95% Confidence Limits) (Figure 2 D). Moreover, SJB2-043 induced apoptosis
of K562 cells in a dose-dependent manner (Figure 2E). Cytotoxic drug concentrations
correlated with the concentrations required for ID1 degradation. In addition, low dose
treatments with SJB2-043 activated differentiation of K562 cells into hemoglobin-
expressing erythroid cells, as detected by benzidine staining (Figure 2F).
In addition to the CML cells (K562 cells), we also evaluated the cytotoxicity of SJB2-043 in
multiple acute myeloid leukemia (AML) cell lines. We chose AML cell lines which were
engineered to express the Luciferase enzyme so that these cell lines can be used in future for
in vivo optical imaging experiments. The AML cell lines, namely, MOLM14, OCI-AML3,
U937 and SK-NO1 (Figure 3) expressed ID1 proteins. Upon treatment with SJB2-043, a
dose-dependent cytotoxicity and concomitant ID1 degradation was observed in all of the
AML cell lines (Figure 3) further suggesting the role of ID1 in leukemic cell survival.
In order to determine if the cytotoxicity of the USP1 inhibitor was due to USP1/ID1
degradation, we next evaluated analogs of SJB2-043 in leukemic cells (Supplementary
Figure 3). The USP1 inhibitor analogs (e.g. SJB2-127) with no significant activity on USP1
(IC50 >10 μM ) or ID1 degradation at concentrations upto 10 μΜ, did not exhibit cytotoxic
effects on leukemic cells (supplementary figure 3A). The analog SJB2-109 had comparable
biochemical inhibitory activity (IC50 =0.416 μM ) to our lead inhibitor SJB2-043 and
exhibits comparable effects on ID1 degradation and leukemic cell survival. Importantly, a
more potent analog SJB3-019A (IC50 = 0.0781 μM) was 5 times more potent than SJB2-043
in promoting ID1 degradation and cytoxicity in K562 cells.
To determine whether ID1 degradation resulted from USP1 inhibition and was not
secondary to apoptosis, we next analyzed USP1/ID1 levels and apoptosis after treating K562
cells with SJB2-043 along with a caspase inhibitor in a time-course manner. USP1/ID1
degradation was observed as early as 7 hrs after the 2 μM of SJB2-043 exposure when
apoptosis was not significant (supplementary figure 4A). At 18 hrs or 26 hrs (supplementary
figures 4B, 4C) after the SJB2-043 exposure (2 μM), complete degradation of USP1/ID1
was observed with concurrent robust increase in apoptosis. As expected, caspase inhibitor
treatment resulted in decreased apoptosis and inhibition of caspase activity (supplementary
figures 4). However, ID1 degradation was not affected by caspase inhibition (supplementary
figures 4, left panels). Even when the caspase activity was significantly abrogated with
caspase inhibitor, the apoptosis was not completely blocked. These results suggest that ID1
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degradation by SJB2-043 may not be occurring as a result of induction of apoptosis,
although apoptosis may play a role in destabilizing ID1 independent of USP1 inhibition.
Collectively, these results indicated that novel USP1 inhibitors promote ID1 degradation by
specifically targeting native USP1 and cause cytotoxicity in multiple leukemic cell lines.
Pimozide, a known USP1 inhibitor, promotes ID1 degradation and inhibits leukemic cell
growth
A known drug, Pimozide, is a weak USP1 non-competitive inhibitor (34). Pimozide may
also inhibit STAT5 activation, thereby reducing the survival of BCR/ABL driven CML cells
(35). We examined Pimozide for its possible cytotoxic effects on K562 cells (Figure 4) via
destabilization of ID1. Interestingly, Pimozide promoted ID1 degradation, decreased USP1
levels, and caused a dose-dependent inhibition of K562 cell growth in vitro with induction
of apoptosis (Figure 4B-D), though at a higher drug concentrations as compared to
SJB2-043. The inhibitory drug concentrations correlated with the concentrations required for
ID1 degradation. We next examined the effect of Pimozide in a mouse xenograft model of
leukemia. K562 cells were injected into nude mice and xenografts were established followed
by the treatment with Pimozide or Vehicle. As shown in Figure 4E, Pimozide treatment
caused a modest inhibition of tumor growth. Taken together, Pimozide, a commercially
available weak USP1 inhibitor, promotes ID1 degradation and inhibits leukemic cell growth
in vitro and in vivo, suggesting that our more potent USP1 inhibitors may have a stronger
anti-leukemic effect.
USP1 inhibitor promotes ID1 degradation and inhibits growth of primary AML cells from
patients
Human AML precursor cells arise from leukemic stem cells (LSCs) and LSC differentiation
is controlled through coordinate transcriptional regulation including the bHLH proteins. We
therefore, tested whether the USP1 inhibitor also promotes ID1 degradation and cytoxicity
in primary human leukemic cells. Primary fresh bone marrow and peripheral blood samples
were acquired from AML patients and mononuclear cells were harvested. The cells were
then exposed to USP1 inhibitor for 48-72 hrs in culture and ID1 levels as well as cell
viability was determined. USP1 inhibitor SJB2-043 exhibited dose-dependent cytotoxicity
on the primary bone marrow as well as peripheral blood from AML patients (Figure 5 A, B).
Moreover, SJB2-043 treatment caused inactivation of USP1 and promoted ID 1 degradation
in primary AML cells (Figure 5C). ID1 protein was detected as a doublet, which is likely
due to the post-translational modification of the protein. These results demonstrate that
USP1 inhibitor SJB2-043 inactivates native USP1 in primary AML cells and exhibits
cytotoxicity. The selectivity of SJB2-043 against normal human hematopoietic cells was
then examined in comparison to Pimozide using cord blood CD34+ cells. Whereas Pimozide
was tolerated at high micromolar doses, low micromolar levels of SJB2-043 did result in
growth inhibition of primary human cord blood CD34+ cells (Supplementary figure 5).
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USP1 inhibitor increases the levels of Ub-FANCD2 and disrupts the homologous
recombination
Previous studies indicate that USP1 has other substrates besides ID1 (36). For instance, the
USP1/UAF1 complex deubiquitinates the cellular monoubiquitinated substrates Ub-
FANCD2 and Ub-PCNA (31, 37). Deubiquitination of FANCD2 is a critical step in the
Fanconi anemia (FA)/BRCA DNA repair pathway (38, 39). Knockout or knockdown of
USP1/UAF1 results in cellular hypersensitivity to DNA cross-linking chemotherapy agents
such as Mitomycin C (40, 41). Murine knockout of USP1 results in cellular increase in Ub-
FANCD2 and a mouse phenotype resembling FA (41). Knockout of USP1 also results in
elevated levels of Ub-PCNA, leading to an increase in DNA translesion synthesis (TLS)
(31).
We next determined whether the USP1 inhibitors can alter cellular levels of Ub-FANCD2
and Ub-FANCI, a binding partner of FANCD2 (Figure 6). Hela cells were treated with
USP1 inhibitor C527 and levels of FANCD2 and FANCI were determined by western
blotting of the cell lysates. C527 treatments caused an increase in the levels of Ub-FANCD2
and Ub-FANCI (Figure 6A). SJB2-043 (another USP1 inhibitor) also increased the level of
Ub-FANCD2 (supplementary figures 6A and 6B). An increase in Ub-PCNA was also
observed in cells exposed to SJB2-043 (supplementary figure 6C) suggesting that besides
FANCD2, PCNA is also affected by USP1 inhibition. Hela cells were next pre-treated with
C527 followed by the treatment with DNA damaging agents including Mitomyin C, a DNA
cross-linking agent. Pre-treatment of cells with USP1 inhibitor caused an enhancement in
the cytoxicity of Mitomycin C and Camptothecin (Figure 6B).
Since disruption of USP1 activity results in decreased homologous recombination (HR)
(41), we next used a gene conversion assay to examine the effect of USP1 inhibitor on
cellular HR activity. Interestingly, C527 treatments caused a dose-dependent decrease in
gene conversion (Figure 6C), based on the measurement of cellular GFP in this assay. We
also confirmed HR defect by evaluating Rad51 foci formation, another surrogate marker of
cellular HR activity (Figure 6D). C527 inhibited Camptothecin induced the Rad51 foci in
Hela cells. The more active USP1 inhibitor SJB3-019A also increased the levels of Ub-
FANCD2 and Ub-PCNA, and decreased the HR activity (supplementary figures 6D-F).
Taken together, these results suggest that USP1 inhibitor treatments lead to an increase in
ubiquitinated forms of FANCD2 and FANCI, causes a decrease in HR activity, and
sensitizes cells to DNA damaging agents.
DISCUSSION
ID1 is essential for proliferation and maintenance of many cancer types (14, 42). However,
it has not yet been therapeutically targeted with a small molecule in leukemia. Here, we
demonstrate that targeting USP1 with a small molecule, can promote ID1 degradation and
cell death in multiple leukemic cell lines. Our data demonstrate that ID1 can be targeted
even in primary human leukemic cells using novel inhibitors of USP1.
The drug of choice for chronic myelogenous leukemia (CML) is Imitanib, although drug
resistance remains a problem. Novel therapies are also needed for the cure of acute
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myelogenous leukemia (AML), the most common acute leukemias of adults. USP1
inhibitors represent a novel class of drugs for these cancers. USP1 inhibitors can degrade
ID1, promote differentiation, and induce apoptosis in these types of leukemic cells and can
be potential therapeutic agents. ID1 blocks cellular differentiation at least in part, through its
repressive effect on the expression of cell cycle inhibitor p21 (20). Consistent with this
previous report (20), our USP1 inhibitor C527 promotes the degradation of ID1 and the
concurrent upregulation of p21 in mouse osteosarcoma cells (supplementary figure 6B). Cell
cycle arrest through p21 upregulation provides a mechanistic explanation for the increase in
erythroid differentiation of leukemic cells. ID proteins have central role in keeping cells in
an immature state. Various reports suggest that ID proteins including ID1 play an important
role in maintaining cancer-initiating cells in a variety of solid tumors (10, 19, 43, 44).
Therefore, therapeutically targeting ID1 may also eradicate leukemic cancer stem cells.
An inhibitor of USP1, Pimozide, was recently identified (34). Pimozide, an antipsychotic
drug, is currently FDA approved for treatment of Tourrete's syndrome. However, its efficacy
in promoting ID1 degradation has not been previously reported. In our studies, Pimozide
promotes ID1 degradation and causes cytoxicity in leukemic cells. Our in vivo studies using
Pimozide showed a modest decrease in tumor volume in xenograft models of K562
leukemic cells. This is consistent with the recent report by Nelson et al (45) who observed a
modest effect of Pimozide in FLT3-AML-driven tumor models. Of note, the EC50 of
Pimozide on leukemic cells is significantly higher than our novel USP1 inhibitors. Even
though Pimozide is currently used in humans for the treatment of Tourrete's syndrome, its
efficacy in mouse tumor models is limited due to its toxicity. Accordingly, at the maximum
tolerated doses, Pimozide may not be an effective anti-cancer agent, at least in leukemic
mouse models. Moreover, in addition to exhibiting an inhibitory activity to USP1, it also
abrogates STAT5 activity in leukemic cells (35, 45).
ID1 plays an important role in invasiveness of many cancer types including breast and brain
tumors (11, 46, 47). Specifically, ID1 depletion by antisense oligos to ID1 in BCR-ABL
bearing 32D3 cells significantly reduces its invasiveness in vitro and in vivo SCID mouse
models via MMP9 axis (48). It remains to be investigated if our small molecule inhibitors of
USP1 can reduce the invasiveness of leukemic cells. Although ID1 has been previously
targeted using peptide-conjugated anti-sense oligomers (49), peptide aptamers (50), or
cannabidiol (11) as potential ways to inhibit ID1 function in solid tumors, none of these
applications have been explored for leukemia.
The USP1 inhibitors reported in this study may have other advantages, since USP1 has other
known substrates (31, 37). We have previously shown that USP1, in complex with its
stimulatory binding partner, UAF1, deubiquitinates the Fanconi Anemia (FA) proteins,
FANCD2 and FANCI (24). Knockdown of USP1 activity results in elevated cellular levels
of Ub-FANCD2, resulting in disruption of the FA pathway (40, 41). Functional Fanconi
anemia DNA repair pathway is required for cellular resistance to DNA cross-linking agents
and FA pathway deficient cells including USP1−/− cells are hypersensitive to DNA cross-
linking agents (39-41). USP1 inhibitors may therefore block the FA pathway, thereby
promoting cellular hypersensitivity to DNA crosslinking agents and chromosome instability.
In the short run, USP1 inhibitors may therefore have an additional useful function as anti-
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cancer agents, by sensitizing tumors to conventional chemotherapeutic agents, e.g. Cisplatin
(34). In our study, USP1 inhibitors increased the levels of Ub-FANCD2, decreased the HR
activity, and sensitized cells to chemotherapy agents Mitomycin C and Camptothecin. The
increase in Ub-FANCD2 may result directly from USP1 inhibition or indirectly from the
DNA damage incurred by USP1 inhibitor exposure. In either case, USP1 inhibition may
have additional anti-cancer functions which extend beyond the promotion of cellular
differentiation. Accordingly, the inhibitors may be useful as radiation or cisplatin sensitizers,
based on their ability to disrupt the FA/BRCA or TLS pathways.
In summary, we have identified novel small molecule inhibitors of USP1 which exhibit
nanomolar IC50 for USP1 activity. These inhibitors also promote ID1 degradation and cause
cytotoxicity in a variety of leukemic cell lines and primary leukemic cells. Further
preclinical assessment of these small molecules in mouse models will determine their
efficacy as novel anti-cancer agents. If successful, these newly identified USP1 inhibitors
can have broader implications and can be valuable therapeutic agents for not only leukemia
but also for other cancer types (e.g. breast cancer and glioblastoma) in which ID1 may be a
prime therapeutic target.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. High-throughput screening and identification of USP1/UAF1 inhibitors
(A) Schematic of the USP1/UAF1 constructs. (B) Coomassie blue staining of the purified
USP1/UAF1 complex (C) A schematic of the Ub-Rhodamine based screening assay (D)
Chemical structure of a parental USP1 inhibitor compound 527 (C527). (E) C527 inhibits
USP1 activity in a time-dependent manner. Purified USP1/UAF1 complex was incubated
with 1 μM C527 or DMSO for the indicated time, followed by the addition of Ub-AMC at a
0.5 μM final concentration. Fluorescence (RFU) at 535 nm was measured to indicate the
enzymatic activity of USP1. (F) Dose-dependent inhibition of USP1 enzymatic activity by
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USP1 inhibitor C527. Purified USP1/UAF1 complex was incubated with C527 or DMSO
for 3 hrs followed by the addition of Ub-AMC at 0.5 μM concentration. The fluorescence
(RFU) at 535 nm was measured to indicate the enzymatic activity of USP1. (G) IC50 plot of
C527 against USP/UAF1 complex in an enzymatic reaction, as described in panels E and F.
(H,I) USP1 inhibitor SJB2-043 1 μM inhibits the activity of native USP1/UAF1. K562 cells
were treated with DMSO or SJB2-043 for 24 hrs and cell extracts were incubated with 0.5
μM Ub-Vs (see structure in panel H) for 45 min. An aliquot of untreated cell extract was
treated with Ubiquitin-aldehyde (Ub-Aldehyde, 5 μM) before adding Ub-Vs. The reactions
were then subjected to immunoblotting with anti-HA or anti-USP1 antibodies.
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Figure 2. USP1 inhibitor promotes ID1 degradation and inhibits growth of the leukemic cell line
K562
(A) Chemical structure of USP1 inhibitor SJB2-043 (B) Western blots of lysates from K562
cells treated with DMSO or USP1 inhibitor SJB2-043 for 24 hrs. (C) Degradation of USP1
and ID1 in leukemic cells by USP1 inhibitor is proteasome mediated. Western blots of the
lysates from K562 cells treated with SJB2-043 for 24 hrs followed by the treatment with
MG-132 are shown. (D) Dose-dependent growth inhibition of K562 cells by USP1 inhibitor
SJB2-043. Cells were grown in triplicate with DMSO or SJB2-043 for 24 hrs, and
cytotoxicity was determined. (E) Induction of apoptosis in K562 cells treated with USP1
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inhibitor. Cells were grown in triplicate with DMSO or SJB2-043 for 24 hrs, and apoptosis
was determined. (F) Differentiation of K562 cells after treatments with low doses of USP1
inhibitor. Benzidine staining of the cells treated with SJB2-043 for 5 days is shown.
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Figure 3. USP1 inhibitor promotes ID1 degradation and causes cytotoxicity in multiple AML cell
lines
(A) Dose-dependent growth inhibition of MOLM14 cells by SJB2-043. Cells were grown in
triplicate in presence of DMSO or SJB2-043 for 24 hrs, and cytotoxicity was determined.
(B) Western blots of the lysates from MOLM14 cells treated with DMSO or SJB2-043 for
24 hrs. (C) Dose-dependent growth inhibition of Luciferase expressing AML cell lines by
SJB2-043. Cells were grown in triplicate in the presence of DMSO or SJB2-043 for 24 hrs,
and cytotoxicity was determined. (D) Western blots of the lysates from Luciferase
expressing AML cells treated with DMSO or SJB2-043 for 24 hrs.
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Figure 4. Treatment of K562 cells with a known USP1 inhibitor, Pimozide, leads to ID1
degradation and growth inhibition
(A) Chemical structure of a known USP1 inhibitor Pimozide (B) Dose-dependent growth
inhibition of K562 cells by Pimozide. Cells were grown in triplicate with DMSO or
Pimozide for 48 hrs and cytotoxicity was determined. (C) Induction of apoptosis in K562
cells treated with Pimozide. Cells were grown in triplicate cultures, as described in “B”, and
apoptosis was determined. (D) Western blots of the lysates from cells treated with DMSO or
Pimozide for 48 hrs. (E) In vivo efficacy of Pimozide in K562 xenograft. Nude mice (n=10
per group) bearing xenografts of K562 cells were injected ip with Pimozide or Vehicle daily
and tumor volumes (Tumor Volume = (width)2 × length/2)) were measured. P value =
0.0042 for Pimozide vs Vehicle groups, using paired t-test.
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Figure 5. USP1 inhibitors promote ID1 degradation and growth inhibition of primary AML cells
from patients
Primary bone marrow cells or peripheral blood mononuclear cells from AML patients were
cultured in triplicate cultures in the presence of DMSO or USP1 inhibitor, and cytotoxicity
was determined. Survival plots of primary AML bone marrow cells (A) or peripheral blood
cells (B) treated with DMSO or SJB2-043 for 48-72 hrs are shown. The data are from 3
different patient samples (N=3 ± SEM). (C) Western blots of the lysates from AML
peripheral blood cells treated with SJB2-043 for 48 hrs.
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Figure 6. USP1 inhibitor increases the levels of Ub-FANCD2, decreases the HR activity, and
sensitizes the cells to chemotherapy agents
(A) Western blots of the lysates from Hela cells treated with DMSO or USP1 inhibitor C527
for 8 hrs. (B) Increased cytotoxicity of C527 on Hela cells in presence of chemotherapy
agents. Cells were treated with C527 (1 μM) for 24 hrs, followed by the treatment with
Mitomycin C (MMC) (0.25 μM), Camptothecin (CPT) (0.1 μM) or Etoposide (0.5 μM) for 4
days, and cell survival was determined. (C) C527 inhibits DRGFP reporter for homologous
recombination repair activity. U2OS-DRGFP cells were transfected with I-SCE-I reporter
plasmid and then exposed to C527 at the indicated concentration for 24 h. Cells were then
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subjected to flow cytometry analysis. The percentage of GFP positive cells was normalized
by solvent vehicle treated group are shown. (D) C527 inhibits camptothecin-induced
RAD51 foci formation. HeLa cells were pre-treated with DMSO or C527 at the indicated
concentration and then exposed to camptothecin (CPT) for 1 hr. RAD51 foci were detected
using immunofluorescence. Data are represented as mean ± SD from three independent
experiments.
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Table 1
IC50 values of USP1 inhibitor C527 for the indicated deubiquitinating enzymes (DUBs).
DUBs IC50 (μM)
USP1 0.88±0.07
USP12/46 5.97±0.37
USP5 1.65±0.42
UCH-L1 >10
UCH-L3 2.18±0.69
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